查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971235

肝病治療市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、設備、最終使用者及治療階段分類

Liver Disease Treatment Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, End User, Treatment Stage
出版日期: | 出版商: Global Insight Services | 英文 440 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計肝病治療市場規模將從2024年的266億美元成長到2034年的448億美元，複合年成長率約為5.4%。肝病治療市場涵蓋旨在治療和控制肝炎、肝硬化和肝癌等肝臟疾病的療法和藥物。推動該市場成長的因素包括肝病盛行率的上升、治療方法的進步以及醫療保健成本的增加。主要趨勢包括生物目標、非侵入性診斷工具和個人化醫療方法的開發。此外，強調肝病早期診斷和有效管理的宣傳宣傳活動和政府措施也進一步推動了市場成長。

由於治療方法的進步和肝病盛行率的上升，肝病治療市場持續發展。藥物治療領域表現突出，其中抗病毒藥物和免疫抑制劑因其在肝病治療中的有效性而處於領先地位。生物製劑和標靶治療作為第二大成長領域，正迅速崛起，提供個人化治療方案，進而改善患者預後。雖然外科手術治療，特別是肝臟移植，仍然十分重要，但微創手術正逐漸成為更受歡迎的選擇。影像學和生物標記檢測等診斷技術的進步有助於早期發現和干涉，從而提高治療成功率。非侵入性診斷技術的興起，反映出治療方式正朝著更以患者為中心的方向發展。包括遠端醫療和遠端監測在內的數位健康解決方案的整合也在不斷擴展，從而實現對患者的持續參與和管理。這些趨勢凸顯了肝病治療領域的巨大投資和創新機會。

市場區隔
類型 肝炎、非酒精性脂肪肝（NAFLD）、酒精性肝病、肝癌、肝硬化
產品 藥品、生物製藥、疫苗和營養補充劑
服務 診斷與治療服務，肝臟移植
科技 基因療法、幹細胞療法、CRISPR、蛋白質體學、生物標記發現
應用領域 臨床和研究應用
裝置 肝功能檢測設備、診斷影像設備、切片檢查設備
最終用戶 醫院、診所、研究所和診斷檢查室
治療階段 早期、中期和高級階段

市場概況：

肝病治療市場呈現動態變化的特點，包括市場佔有率分佈、定價策略和產品創新。生物技術和製藥研究的進步正推動該領域新產品的大量湧現。各公司正透過提供創新治療方案來策略性地佔據市場佔有率。價格競爭依然激烈，受生產成本、監管核准和市場需求等因素的影響。北美和歐洲佔據主導的市場佔有率，而亞太地區由於醫療保健投資的增加，已成為關鍵的成長區域。肝病治療市場的競爭異常激烈，主要企業正致力於研發以獲得競爭優勢。競爭基準分析包括產品療效、安全性以及成本效益。監管的影響至關重要，嚴格的指導方針影響產品核可和市場准入。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等機構制定的安全和創新標準政策塑造市場格局。策略聯盟、併購推動了市場擴張和滲透，進一步明確了市場結構。

主要趨勢和促進因素：

受全球肝病盛行率不斷上升的推動，肝病治療市場正經歷強勁成長。主要趨勢包括新型治療藥物的研發以及先進技術在治療通訊協定的應用。生物製藥公司正大力投資研發，以期將創新解決方案推向市場，滿足尚未滿足的醫療需求。非酒精性脂肪肝病 (NAFLD) 和肝炎發生率的不斷上升，以及人口老化，都推動了對有效治療方法的需求。各國政府和醫療機構對早期診斷和介入的重視，進一步促進了市場擴張。此外，精準醫療和個人化治療的興起正在革新患者照護，提供量身定做的治療方案，從而改善治療效果。新興市場擁有完善的醫療基礎設施，並不斷擴大先進療法的覆蓋範圍，這些市場蘊藏著許多機會。能夠提供經濟高效且擴充性解決方案的公司，將更有機會掌握這些機會。此外，製藥公司與研究機構之間的合作正在促進創新，並加速下一代治療方法的研發。由於技術進步和對改善患者生活品質的關注，肝病治療市場預計將持續成長。

限制與挑戰：

肝病治療市場面臨許多重大限制與挑戰。其中一個主要挑戰是創新治療方法高成本，限制了低收入群體患者的就醫途徑。許多醫療系統難以負擔這些治療費用，導致醫療資源分配不均和治療效果不佳。此外，監管障礙和冗長的核准流程也延緩了新治療方法的推廣，阻礙了創新和市場擴張。肝病是一種病因和症狀多樣的複雜疾病，診斷和治療難度較高。這種複雜性需要專業的知識和設備，可能導致誤診和延誤治療，進而影響患者的治療效果。此外，訓練有素的肝病專科醫護人員嚴重短缺，限制了有效管理日益成長的病患群體的能力。最後，與肝病相關的社會污名，尤其是生活方式相關疾病，可能會阻礙患者及時就醫，進一步加重醫療系統的負擔，並阻礙市場成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 肝炎
    • 非酒精性脂肪肝（NAFLD）
    • 酒精性肝臟疾病
    • 肝癌
    • 肝硬化
  • 市場規模及預測：依產品分類
    • 製藥
    • 生物製藥
    • 疫苗
    • 營養保健品
  • 市場規模及預測：依服務分類
    • 診斷
    • 治療服務
    • 肝臟移植
  • 市場規模及預測：依技術分類
    • 基因治療
    • 幹細胞療法
    • CRISPR
    • 蛋白質體學
    • 生物標記發現
  • 市場規模及預測：依應用領域分類
    • 臨床應用
    • 研究用途
  • 市場規模及預測：依設備分類
    • 肝功能檢測設備
    • 診斷影像設備
    • 切片檢查裝置
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 臨床科
    • 研究所
    • 診斷檢查室
  • 市場規模及預測：依治療階段分類
    • 早期
    • 中級階段
    • 晚期

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Intercept Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Galectin Therapeutics
  • Conatus Pharmaceuticals
  • Akero Therapeutics
  • Gilead Sciences
  • Ascletis Pharma
  • Genfit
  • CymaBay Therapeutics
  • Arbutus Biopharma
  • Hepion Pharmaceuticals
  • Enyo Pharma
  • Alnylam Pharmaceuticals
  • Mirum Pharmaceuticals
  • Albireo Pharma
  • Spring Bank Pharmaceuticals
  • Viking Therapeutics
  • Zydus Cadila
  • BioVie

第9章：關於我們

簡介目錄
Product Code: GIS33159

Liver Disease Treatment Market is anticipated to expand from $26.6 billion in 2024 to $44.8 billion by 2034, growing at a CAGR of approximately 5.4%. The Liver Disease Treatment Market encompasses therapies and medications aimed at managing and curing liver conditions, including hepatitis, cirrhosis, and liver cancer. This market is driven by increasing liver disease prevalence, advancements in treatment modalities, and rising healthcare expenditure. Key trends include the development of targeted biologics, non-invasive diagnostic tools, and personalized medicine approaches. The market's growth is further fueled by awareness campaigns and government initiatives, emphasizing early diagnosis and effective management of liver diseases.

The Liver Disease Treatment Market is evolving, driven by advancements in therapeutic approaches and increasing disease prevalence. The drug therapy segment leads in performance, with antiviral drugs and immunosuppressants at the forefront due to their efficacy in managing liver conditions. Biologics and targeted therapies are gaining momentum as the second-highest performing segment, offering personalized treatment options that improve patient outcomes. The surgical treatment segment, particularly liver transplantation, remains critical, yet minimally invasive procedures are emerging as a preferred alternative. Diagnostic advancements, such as imaging technologies and biomarker testing, support early detection and intervention, enhancing treatment success rates. Non-invasive diagnostic techniques are on the rise, reflecting a shift towards patient-friendly approaches. The integration of digital health solutions, including telemedicine and remote monitoring, is also expanding, enabling continuous patient engagement and management. These trends highlight significant opportunities for investment and innovation within the liver disease treatment landscape.

Market Segmentation
TypeHepatitis, Non-Alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease, Liver Cancer, Cirrhosis
ProductPharmaceuticals, Biologics, Vaccines, Nutraceuticals
ServicesDiagnostics, Therapeutic Services, Liver Transplantation
TechnologyGene Therapy, Stem Cell Therapy, CRISPR, Proteomics, Biomarker Discovery
ApplicationClinical Applications, Research Applications
DeviceLiver Function Test Devices, Imaging Devices, Biopsy Devices
End UserHospitals, Clinics, Research Institutes, Diagnostic Laboratories
Treatment StageEarly Stage, Intermediate Stage, Advanced Stage

Market Snapshot:

The Liver Disease Treatment Market is characterized by a dynamic landscape of market share distribution, pricing strategies, and product innovations. This sector is witnessing a surge in new product launches, driven by advancements in biotechnology and pharmaceutical research. Companies are strategically positioning themselves to capture market share by offering innovative treatment solutions. Pricing remains competitive, influenced by factors such as production costs, regulatory approvals, and market demand. North America and Europe lead in terms of market share, with Asia-Pacific emerging as a significant growth region due to increasing healthcare investments. Competition in the Liver Disease Treatment Market is intense, with key players focusing on research and development to gain a competitive edge. Benchmarking against competitors involves analyzing product efficacy, safety profiles, and cost-effectiveness. Regulatory influences play a crucial role, with stringent guidelines impacting product approvals and market entry. The market is shaped by policies from agencies such as the FDA and EMA, which dictate standards for safety and innovation. The landscape is further defined by strategic alliances, mergers, and acquisitions, facilitating expansion and market penetration.

Geographical Overview:

The liver disease treatment market is witnessing substantial growth across various regions, each presenting unique opportunities. North America dominates the landscape, driven by advanced healthcare infrastructure and a high prevalence of liver diseases. The region's robust research and development initiatives further bolster market expansion. Europe follows, with significant attention to innovative treatment modalities and government support for liver disease management. Asia Pacific is rapidly emerging as a key growth pocket, propelled by increasing healthcare investments and rising awareness about liver health. China and India are at the forefront, with expanding healthcare sectors and a growing patient population. In Latin America, Brazil shows promising potential as healthcare advancements and economic development fuel market growth. The Middle East & Africa region is gradually gaining momentum, with countries like the UAE investing in healthcare infrastructure and liver disease treatment. These emerging markets present lucrative opportunities for stakeholders aiming to expand their footprint in the liver disease treatment arena.

Key Trends and Drivers:

The Liver Disease Treatment Market is experiencing robust growth, propelled by the rising prevalence of liver diseases worldwide. Key trends include the development of novel therapeutics and the integration of advanced technologies in treatment protocols. Biopharmaceutical companies are investing heavily in research and development to bring innovative solutions to market, addressing unmet medical needs. The increasing incidence of non-alcoholic fatty liver disease (NAFLD) and hepatitis, coupled with the aging population, is driving demand for effective treatments. Governments and healthcare organizations are emphasizing early diagnosis and intervention, further boosting market expansion. Moreover, the advent of precision medicine and personalized therapies is revolutionizing patient care, providing tailored treatment options that improve outcomes. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced treatments is expanding. Companies that can deliver cost-effective and scalable solutions are well-positioned to capitalize on these opportunities. Additionally, collaborations between pharmaceutical firms and research institutions are fostering innovation and accelerating the development of next-generation therapies. The Liver Disease Treatment Market is poised for sustained growth, driven by technological advancements and a focus on enhancing patient quality of life.

Restraints and Challenges:

The liver disease treatment market is confronted with several significant restraints and challenges. A primary challenge is the high cost of innovative therapies, which restricts access for patients in lower-income regions. Many healthcare systems struggle to afford these treatments, leading to unequal access and outcomes. Additionally, regulatory hurdles and lengthy approval processes delay the introduction of new therapies, stifling innovation and market expansion. The complexity of liver disease, with its various etiologies and manifestations, complicates diagnosis and treatment, requiring specialized knowledge and equipment. This complexity can result in misdiagnosis or delayed treatment, impacting patient outcomes. Furthermore, there is a shortage of skilled healthcare professionals trained in hepatology, which limits the capacity to manage the growing patient population effectively. Lastly, the stigma associated with liver diseases, particularly those linked to lifestyle choices, can deter patients from seeking timely medical intervention, further exacerbating the burden on healthcare systems and hindering market growth.

Key Players:

Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Dicerna Pharmaceuticals, Galectin Therapeutics, Conatus Pharmaceuticals, Akero Therapeutics, Gilead Sciences, Ascletis Pharma, Genfit, CymaBay Therapeutics, Arbutus Biopharma, Hepion Pharmaceuticals, Enyo Pharma, Alnylam Pharmaceuticals, Mirum Pharmaceuticals, Albireo Pharma, Spring Bank Pharmaceuticals, Viking Therapeutics, Zydus Cadila, BioVie

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Treatment Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hepatitis
    • 4.1.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
    • 4.1.3 Alcoholic Liver Disease
    • 4.1.4 Liver Cancer
    • 4.1.5 Cirrhosis
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biologics
    • 4.2.3 Vaccines
    • 4.2.4 Nutraceuticals
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostics
    • 4.3.2 Therapeutic Services
    • 4.3.3 Liver Transplantation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Therapy
    • 4.4.2 Stem Cell Therapy
    • 4.4.3 CRISPR
    • 4.4.4 Proteomics
    • 4.4.5 Biomarker Discovery
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Clinical Applications
    • 4.5.2 Research Applications
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Liver Function Test Devices
    • 4.6.2 Imaging Devices
    • 4.6.3 Biopsy Devices
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Clinics
    • 4.7.3 Research Institutes
    • 4.7.4 Diagnostic Laboratories
  • 4.8 Market Size & Forecast by Treatment Stage (2020-2035)
    • 4.8.1 Early Stage
    • 4.8.2 Intermediate Stage
    • 4.8.3 Advanced Stage

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Treatment Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Treatment Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Treatment Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Treatment Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Treatment Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Treatment Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Treatment Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Treatment Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Treatment Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Treatment Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Treatment Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Treatment Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Treatment Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Treatment Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Treatment Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Treatment Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Treatment Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Treatment Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Treatment Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Treatment Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Treatment Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Treatment Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Treatment Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Treatment Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Intercept Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Madrigal Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Dicerna Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Galectin Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Conatus Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Akero Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Gilead Sciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ascletis Pharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Genfit
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 CymaBay Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Arbutus Biopharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Hepion Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Enyo Pharma
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Alnylam Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Mirum Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Albireo Pharma
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Spring Bank Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Viking Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Zydus Cadila
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 BioVie
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us